OSAT yields 53.33% · JNJ yields 2.13%● Live data
📍 OSAT pulled ahead of the other in Year 1
Combined, OSAT + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of OSAT + JNJ for your $10,000?
Orbsat Corp., together with its subsidiaries, provides mobile satellite services (MSS) solutions for satellite-enabled voice, data, personnel and asset tracking, machine-to-machine, and Internet of Things (IoT) connectivity services in the United States and internationally. Its solutions include satellite communications, IoT tracking, and Internet, as well as emergency locator beacons. The company also provides tracking and monitoring solutions using automatic identification system, 2G-5G, push-to-talk, and two-way radio technology; and sells MSS related equipment. In addition, it operates GTCTrack, a subscription-based mapping and tracking portal that provides cloud-based data visualization and management platform that allow managers to track, command, and control assets in near-real-time; and a short-term rental service for customers to use equipment for a limited time period. The company provides its solutions for businesses, governments, military, humanitarian organizations, and individual users to communicate, connect to internet, track and monitor remote assets and lone workers, or request SOS assistance via satellite. It offers its products and services directly to end users and reseller networks; operates e-commerce websites that offer a range of MSS products and solutions; and offers portable satellite voice, data, and tracking solutions through various third-party e-commerce storefronts. The company was formerly known as Orbital Tracking Corp and changed its name to Orbsat Corp. in August 2019. Orbsat Corp. was incorporated in 1997 and is headquartered in Aventura, Florida.
Full OSAT Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.